Jennifer J. Rhodes - 24 Mar 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, CHIEF LEGAL OFFICER, SEC
Signature
/s/ Jennifer J. Rhodes
Issuer symbol
ACAD
Transactions as of
24 Mar 2025
Net transactions value
$0
Form type
4
Filing time
26 Mar 2025, 20:03:28 UTC
Previous filing
08 Feb 2024
Next filing
10 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACAD Common Stock 1,020 24 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +102,289 $0.000000 102,289 24 Mar 2025 Common Stock 102,289 $17.23 Direct F2
transaction ACAD Restricted Stock Units Award $0 +30,062 $0.000000 30,062 24 Mar 2025 Common Stock 30,062 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on November 15, 2024.
F2 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F3 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F4 The restricted stock units vest in four equal annual installments beginning March 24, 2026.